New hope for rare blood cancer patients: experimental drug combo shows promise in early trial
NCT ID NCT04984837
First seen Apr 23, 2026 · Last updated Jun 17, 2026 · Updated 9 times
Summary
This study tests whether adding the experimental drug lacutamab to standard chemotherapy (GemOx) helps control peripheral T-cell lymphoma, a rare blood cancer, in people whose cancer has returned or stopped responding to prior treatments. About 49 adults with a specific marker (KIR3DL2) on their cancer cells will be randomly assigned to receive either the drug combo or chemo alone. The goal is to see if the combination delays cancer growth or spread, but this is not a cure—patients may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A. Z. Sint-Jan
Bruges, Belgium
-
APHP - Hopital Necker
Paris, France
-
APHP - Hôpital Henri Mondor
Créteil, France
-
APHP - Hôpital Saint Antoine
Paris, France
-
APHP - Hôpital Saint Louis
Paris, France
-
APHP - Hôpital de la Pitié Salpétrière
Paris, France
-
CH Métropole Savoie
Chambéry, France
-
CH d Avignon - Hopital Henri Duffaut
Avignon, France
-
CH de Bretagne Atlantique - Hopital Chubert
Vannes, France
-
CH de Dunkerque
Dunkirk, France
-
CH de Mulhouse
Mulhouse, France
-
CH de Perpignan
Perpignan, France
-
CH de Périgueux
Périgueux, France
-
CH de la Côte Basque - Hôpital de Bayonne
Bayonne, France
-
CH du Mans
Le Mans, 72000, France
-
CHD de Vendée
La Roche-sur-Yon, France
-
CHR Verviers
Verviers, Belgium
-
CHR d'Orléans
Orléans, France
-
CHRU de Lille - Hôpital Claude Hurriez
Lille, France
-
CHU Dinant Godinne - UCL Namur - YVOIR
Yvoir, Belgium
-
CHU d'Amiens
Amiens, France
-
CHU d'Angers
Angers, France
-
CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie
Pessac, France
-
CHU de Caen - Côte de Nacre - IHBN
Caen, France
-
CHU de Clermont Ferrand - Estaing
Clermont-Ferrand, France
-
CHU de Dijon BOURGOGNE - Hôpital François Mitterand
Dijon, France
-
CHU de Grenoble - Hôpital Albert Michallon
La Tronche, France
-
CHU de LIEGE - Domaine Sart Tilman
Liège, Belgium
-
CHU de Montpellier
Montpellier, France
-
CHU de Nancy - Brabois
Nancy, France
-
CHU de Nantes - Hôtel Dieu
Nantes, France
-
CHU de Nîmes
Nîmes, France
-
CHU de Poitiers - Hôpital de La Milétrie
Poitiers, France
-
CHU de Reims
Reims, France
-
CHU de Rennes - Hôpital de Pontchaillou
Rennes, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier Annecy Genevois
Pringy, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
-
Centre Leon Berard
Lyon, 69373, France
-
Ch de Versailles - Hopital Andre Mignot
Le Chesnay, France
-
Charite Universitat Smedizin Berlin
Berlin, Germany
-
Chu de Limoges - Hopital Dupuytren
Limoges, France
-
Chu de Meaux
Meaux, France
-
Clinique CHC MontLégia
Liège, Belgium
-
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Brussels, Belgium
-
Cliniques universitaires Saint-Luc - Université catholique de Louvain
Brussels, Belgium
-
GEORG-AUGUST-UNIV, GOETTINGEN - Klinik fur Haematologie und Medizini
Goettigen, Germany
-
Grand Hôpital de Charleroi
Charleroi, Belgium
-
HELORA - Hôpital de La LouvièreSite Jolimont
Haine-Saint-Paul, Belgium
-
Hospital Clínico Universitario de Valencia
Valencia, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario Fundacion Jimenez Diaz - Hematologia
Madrid, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, Spain
-
Hôpital Saint Vincent-De-Paul
Lille, France
-
Institut Bergonié
Bordeaux, France
-
Institut Jules Bordet
Anderlecht, Belgium
-
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, 31100, France
-
Institut de Cancerologie Strasbourg Europe
Strasbourg, France
-
Institut de Cancérologie et d'Hématologie Universitaire de Saint-Étienne
Saint-Etienne, France
-
UNIVERSITAT LEIPZIG - Klinik fur Hamatologie, Zelltherapie und Hamostaseo
Leipzig, Germany
-
UNIVERSITATSKLINIKUM REGENSBURG - Klinik für Innere Medizin III
Regensburg, Germany
-
UZ Antwerpen
Edegem, Belgium
-
Universitatsklinikum Halle (Saale)
Halle, Germany
-
VZW ZAS
Antwerp, Belgium
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.